Aberdeen Asset Management PLC UK increased its stake in shares of C R Bard Inc (NYSE:BCR) by 2.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 64,454 shares of the medical instruments supplier’s stock after buying an additional 1,242 shares during the period. Aberdeen Asset Management PLC UK’s holdings in C R Bard were worth $16,019,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Haverford Trust Co. raised its stake in C R Bard by 0.3% in the fourth quarter. Haverford Trust Co. now owns 4,012 shares of the medical instruments supplier’s stock valued at $901,000 after buying an additional 11 shares in the last quarter. Keybank National Association OH raised its stake in C R Bard by 0.3% in the fourth quarter. Keybank National Association OH now owns 4,353 shares of the medical instruments supplier’s stock valued at $978,000 after buying an additional 13 shares in the last quarter. ETRADE Capital Management LLC raised its stake in C R Bard by 1.7% in the third quarter. ETRADE Capital Management LLC now owns 1,054 shares of the medical instruments supplier’s stock valued at $236,000 after buying an additional 18 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in C R Bard by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,215 shares of the medical instruments supplier’s stock valued at $947,000 after buying an additional 20 shares in the last quarter. Finally, Burns J W & Co. Inc. NY raised its stake in C R Bard by 1.3% in the first quarter. Burns J W & Co. Inc. NY now owns 1,581 shares of the medical instruments supplier’s stock valued at $393,000 after buying an additional 21 shares in the last quarter. Institutional investors own 86.89% of the company’s stock.

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

C R Bard Inc (BCR) traded down 0.02% during midday trading on Tuesday, hitting $313.21. The stock had a trading volume of 151,138 shares. C R Bard Inc has a 1-year low of $203.63 and a 1-year high of $313.88. The stock’s 50-day moving average is $299.56 and its 200-day moving average is $251.49. The company has a market capitalization of $22.68 billion, a PE ratio of 39.86 and a beta of 0.63.

C R Bard (NYSE:BCR) last announced its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, beating the Zacks’ consensus estimate of $2.65 by $0.22. C R Bard had a net margin of 14.31% and a return on equity of 48.48%. The firm had revenue of $938.80 million during the quarter, compared to the consensus estimate of $916.15 million. During the same quarter last year, the firm earned $2.34 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. Equities research analysts forecast that C R Bard Inc will post $11.78 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, May 12th. Investors of record on Monday, May 1st were issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date was Thursday, April 27th. C R Bard’s payout ratio is 14.77%.

WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/c-r-bard-inc-bcr-stake-increased-by-aberdeen-asset-management-plc-uk/1337802.html.

Several equities research analysts recently issued reports on BCR shares. Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $276.00 price objective for the company in a research note on Friday, March 3rd. BMO Capital Markets reissued a “buy” rating and set a $255.00 price objective on shares of C R Bard in a research note on Tuesday, April 11th. Jefferies Group LLC reissued a “hold” rating and set a $237.00 price objective on shares of C R Bard in a research note on Monday, March 27th. Wells Fargo & Co lowered C R Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. Finally, Raymond James Financial, Inc. lowered C R Bard from a “strong-buy” rating to a “mkt perform” rating in a research note on Wednesday, April 26th. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $265.62.

In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the completion of the transaction, the vice president now owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.97% of the stock is currently owned by company insiders.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C R Bard Inc (NYSE:BCR).

Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.